(S)-4-Methyl-2-methylamino-pentanoic acid methylamide | 390755-61-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-4-Methyl-2-methylamino-pentanoic acid methylamide
• 英文别名: (2S)-N,4-dimethyl-2-(methylamino)pentanamide
• CAS: 390755-61-0
• 化学式: C₈H₁₈N₂O
• 分子量: 158.244
• InChiKey: FEPOARYFCLWDHV-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-4-Methyl-2-methylamino-pentanoic acid methylamide 、 乙酰氯 在 三乙胺 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 0.5h， 生成 (S)-2-(Acetyl-methyl-amino)-4-methyl-pentanoic acid methylamide
  参考文献：
  名称：

  Hlavacek, Jan; Fric, Ivo; Budesinsky, Milos, Collection of Czechoslovak Chemical Communications, 1988, vol. 53, # 11A, p. 2473 - 2494

  摘要：

  DOI：
• 作为产物：
  描述：

  (2S)-(N-para-toluenesulphonylamino)-4-methylpentanoic acid tert-butyl ester 在 sodium hydroxide 、 calcium 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 氨 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.52h， 生成 (S)-4-Methyl-2-methylamino-pentanoic acid methylamide
  参考文献：
  名称：

  Hlavacek, Jan; Fric, Ivo; Budesinsky, Milos, Collection of Czechoslovak Chemical Communications, 1988, vol. 53, # 11A, p. 2473 - 2494

  摘要：

  DOI：

文献信息

• DPP4 INHIBITOR AND PHARMACEUTICAL USE THEREOF
  申请人：Ijichi Chiori

  公开号：US20080175837A1

  公开（公告）日：2008-07-24

  The present invention provides a Dpp4 inhibitor which comprises a leucine derivative of the following formula (1) or a methionine derivative of the following formula (2): wherein each R1 and R3 represents a hydrogen atom (H) and an L-amino acid residue; R2 represents a hydroxyl group (OH), alkoxy group having 1 to 6 carbon atoms, amino group (NH2), alkylamino group having 1 to 6 carbon atoms, glycine residue, β-alanine residue, L-amino acid (except for proline, alanine and phenylalanine) residue or L-amino-acid amide (except for proline amide, alanine amide and phenylalanine amide) residue; and R4 represents a hydroxyl group (OH), alkoxy group having 1 to 6 carbon atoms, amino group (NH2), alkylamino group having 1 to 6 carbon atoms, glycine residue, β-alanine residue, L-amino acid (except for proline and alanine) residue or L-amino-acid amide (except for proline amide and alanine amide) residue. These derivatives also act as autophagy regulators.

  本发明提供了一种Dpp4抑制剂，其包括以下式(1)的亮氨酸衍生物或以下式(2)的甲硫氨酸衍生物：其中每个R1和R3代表氢原子（H）和L-氨基酸残基；R2代表羟基（OH），具有1到6个碳原子的烷氧基，氨基（NH2），具有1到6个碳原子的烷基氨基，甘氨酸残基，β-丙氨酸残基，L-氨基酸（除脯氨酸、丙氨酸和苯丙氨酸外）残基或L-氨基酸酰胺（除脯氨酸酰胺、丙氨酸酰胺和苯丙氨酸酰胺外）残基；以及R4代表羟基（OH），具有1到6个碳原子的烷氧基，氨基（NH2），具有1到6个碳原子的烷基氨基，甘氨酸残基，β-丙氨酸残基，L-氨基酸（除脯氨酸和丙氨酸外）残基或L-氨基酸酰胺（除脯氨酸酰胺和丙氨酸酰胺外）残基。这些衍生物还作为自噬调节剂。
• COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES
  申请人：Rothbard Jonathan B.

  公开号：US20110206610A1

  公开（公告）日：2011-08-25

  This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

  本发明提供了用于增强药物和其他药剂通过上皮组织的传递的组合物和方法，包括皮肤、胃肠道、肺上皮、眼组织等。这些组合物和方法也适用于通过内皮组织的传递，包括血脑屏障。这些组合物和方法采用了一种传递增强转运体，该转运体具有足够的鸟氨酸或酰胺基侧链基团，以增强与试剂结合的化合物通过一层或多层组织的传递，相对于未结合的化合物。传递增强聚合物包括例如，长度在6到25个残基之间的多鸟氨酸分子。
• CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP3636807A1

  公开（公告）日：2020-04-15

  The present inventors have found that when screening for cyclic peptide compounds that can specifically bind to a target molecule, the use of a library including cyclic peptide compounds having a long side chain in the cyclic portion can improve the hit rate for cyclic peptide compounds that can specifically bind to the target molecule. Meanwhile, the present inventors have found that tryptophan and tyrosine residues, which have conventionally been used in oral low molecular-weight pharmaceuticals and are amino acid residues having an indole skeleton or a hydroxyphenyl group, are not suitable for peptides intended to attain high membrane permeability.

  本发明人发现，在筛选能与目标分子特异性结合的环肽化合物时，使用包括环状部分具有长侧链的环肽化合物库，可以提高能与目标分子特异性结合的环肽化合物的命中率。同时，本发明者发现色氨酸和酪氨酸残基不适合用于旨在获得高膜渗透性的肽，这两种残基通常用于口服低分子量药物，是具有吲哚骨架或羟基苯基的氨基酸残基。
• DERIVATIVES OF CYCLOSPORIN A
  申请人：Cypralis Limited

  公开号：EP2376524B1

  公开（公告）日：2017-03-15
• NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION
  申请人：S&T Global Inc.

  公开号：EP2646043B1

  公开（公告）日：2017-02-15